Juncell Therapeutics

Focus: Juncell Therapeutics is a Shanghai-based biotechnology company focused on tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors across oncology indications.

Oncology Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Juncell Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Juncell Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

19 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

GC203 TIL

Pancreatic Cancer

Phase 1

Clinical Trials (1)

NCT06828328A Study of GC203 TIL in PDCA (RJ)

Phase 1

Help build intelligence for Juncell Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage cell therapy platform with broad pipeline across 19 clinical trials spanning melanoma, lung, breast, pancreatic, liver, and gynecologic cancers
Positioned in high-growth TIL cell therapy space with potential for significant clinical validation as Phase 2 melanoma program advances
Based in China with access to emerging Asian oncology markets and growing cell therapy infrastructure

Watch Out For

No active job openings (0 positions listed) suggests minimal near-term hiring or company is in stealth mode
Extremely early-stage pipeline (18 Phase 1 programs, only 2 Phase 2) with no Phase 3 data, meaning 5-10 year timeline to potential commercialization

Generated by Claude from Juncell Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Tumor Infiltrating Lymphocyte

Advanced Melanoma

Phase 1

Clinical Trials (1)

NCT05098184A Study of GC101 TIL in Advanced Melanoma (10hospital)

Phase 1

Tumor Infiltrating Lymphocytes

Breast Cancer

Phase 1

Clinical Trials (1)

NCT05142475A Study of GC101 TIL in Advanced Breast Cancer (10hospital)

Phase 1